Oxford Technology & Innovations EIS Fund (OTIF) invests £1.6m into University of Oxford spinout company OrganOx Ltd
- OrganOx Ltd. is commercialising the metra L, the world’s first normothermic liver perfusion device.
- OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a £6.4 million round led by Oxford Investment Consultants LLP.
- Funding will accelerate a number of programmes in OrganOx’s R&D pipeline, with a Phase I clinical trial for a normothermic kidney perfusion device due to start later this year.
- This investment in OrganOx Ltd., brings the total funds invested by OTIF in the Company to £5.6m.
Oxford Investment Consultants LLP (OIC) is pleased to announce a £1,638,175 investment from the Oxford Technology and Innovations EIS Fund (OTIF) into OrganOx Ltd., a spinout from Oxford University’s Institute of Biomedical Engineering (IBME). OrganOx’s first product, the metra, is transforming liver transplantation, improving the viability and supply of donor organs. During preservation with the metra, the liver is continuously perfused with oxygenated blood, medications and nutrients at normal body temperature and physiological pressures and flows for up to 24 hours. This means the liver is functional throughout preservation allowing for evidence-based decisions on whether to transplant a donor organ. The metra has supported more than 1,000 liver transplants globally.
The investment is part of a £6.4 million equity funding round led by OIC and supported by both existing and new shareholders. This funding will enable the Company to accelerate a number of programmes in its R&D pipeline, with a Phase I trial for a normothermic kidney perfusion device due to start later this year. As with liver transplantation, there is a clear unmet clinical need for technologies to improve the utilisation of donated kidneys, to reduce waiting list mortality and ensure more patients can benefit from a life changing transplant.
The fundraise was a qualified financing conversion event and enabled the conversion of the £5.35 million of convertible loans from August 2020 to be converted into equity, transforming OrganOx’s balance sheet.
Dr Oern Stuge, OrganOx Chair, commented:
“The Company faces an important year with continued commercial rollout in UK & Europe and preparations to launch commercial activities in the US, pending FDA approval.”
Craig Marshall, OrganOx CEO, commented:
“We were absolutely delighted to complete the fundraise and by the support and encouragement we received from our shareholders. OrganOx now has a strong balance sheet and this best positions us for closing regulatory process with FDA in seeking marketing approval and commercialisation in the US, building the momentum of adoption of NMP across our broadening UK & European customer base, whilst also confidently investing in and accelerating our R&D programmes. We have a very exciting twelve months ahead and lots to achieve.”
George Robinson, Founding Partner at Oxford Investment Consultants LLP, commented:
“We are thrilled to continue to support OrganOx through a crucial time in its development. OrganOx is addressing a clear unmet need in the transplant market with its normothermic perfusion devices, improving the viability and supply of donor organs. This ground-breaking technology has the ability to significantly transform the lives of many thousands of people that spend several years on the organ transplant waiting list. We look forward to supporting the team as they seek US market approval and expand the reach of their lifesaving technology to the patients that need it.”
Further information on OIC, OTIF and OrganOx Ltd. can be found here